Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2018 Nov;81:330–331. doi: 10.1016/j.actbio.2018.10.009

Corrigendum to “Short peptide analogs as alternatives to collagen in pro-regenerative corneal implants” [Acta Biomaterialia 69 (2018) 120–130]

Jaganmohan R Jangamreddy a,g, Michel KC Haagdorens b,c,1, M Mirazul Islam a,1, Philip Lewis d,1, Ayan Samanta a, Per Fagerholm a, Aneta Liszka a, Monika K Ljunggren a, Oleksiy Buznyk a, Emilio I Alarcon e, Nadia Zakaria b,c,, Keith M Meek d,, May Griffith a,f,
PMCID: PMC6237672  PMID: 30385236

The authors regret that they missed a detail in the Materials and Methods, section, 2.1 Hydrogel implants. Although the CLP sequences were identical, the peptides were synthesized at two different places using the same chemistry. So, to clarify, the first two sentences of the first paragraph should read as follows:

“CLP-PEG and RHCIII-MPC implants were prepared as previously described for the mini-pig studies [4,15]. For all other studies, briefly, CLP comprising Cys-Gly-(Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4, was synthesized (UAB Ferentis, Vilnius, Lithuania) and conjugated to a 40 kDa 8 arm PEG-maleimide (Creative PEG Works, NC, USA) by continually stirring in ddH2O at pH 4.5 for 2 days at a molar ratio of 32:1 and then dialyzed against distilled water using 12–14 kDa MWCO tubing for 2–3 days before lyophilization.”

There is also a transcription error in Table 1, where data entered for “Aesthesiometry” is incorrect. We have now corrected this error in the revised Table 1 below.

Table 1.

Progress of CLP-PEG and RHCIII-MPC implants grafted into corneas of mini-pigs, compared to untreated contralateral control eyes over the 12 month post-operation period.

Treatment Time Cornea thickness (mm) Haze Vascularization
Schirmer's tear test (mm) Aesthesiometry (mm) IOP (mmHg)
Implant Margin
CLP-PEG Pre-op 706 ± 20 0 0 0 12 ± 3 3.9 ± 0.3 10 ± 1
1 m 0.38 0.5 1.75 7 ± 1 0
3 m 690 ± 16 0.25 1.75 0 13 ± 3 1.3 ± 0.4 16 ± 2
6 m 702 ± 22 0 0 0.75 12 ± 1 3.4 ± 0.1 16 ± 2
9 m 724 ± 13 0 0 0.5 16 ± 2 2.9 ± 0.1 19 ± 8
12 m 747 ± 8 0 0 2 13 ± 4 3.4 ± 0.1 22 ± 2



RHCIII-MPC Pre-op 704 ± 21 0 0 0 11 ± 3 4.4 ± 0.6 11 ± 1
1 m 0.38 0.5 0.5 7 ± 2 0
3 m 652 ± 9 0.69 1.75 0.5 15 ± 2 0.4 ± 0.4 14 ± 2
6 m 669 ± 22 0 0 2 13 ± 2 3.3 ± 0.4 20 ± 2
9 m 687 ± 11 0 0 0 13 ± 4 2.9 ± 0.2 16 ± 2
12 m 693 ± 23 0 0 0 15 ± 4 3.8 ± 0.1 15 ± 1



Untreated Pre-op 725 ± 11 0 0 0 8 ± 2 4.4 ± 0.3 11 ± 1
1 m 0 0 0 9 ± 1 4.1 ± 0.4
3 m 730 ± 10 0 0 0 12 ± 2 3.4 ± 0.1 17 ± 2
6 m 738 ± 10 0 0 0 10 ± 1 3.9 ± 0.1 17 ± 3
9 m 747 ± 11 0 0 0 13 ± 3 3.3 ± 0.3 16 ± 6
12 m 767 ± 11 0 0 0 15 ± 2 3.6 ± 0.2 18 ± 2

The authors apologize for any confusion or inconvenience caused.

Contributor Information

Nadia Zakaria, Email: nadia.zakaria@uantwerpen.be.

Keith M. Meek, Email: MeekKM@cardiff.ac.uk.

May Griffith, Email: May.Griffith@umontreal.ca.

RESOURCES